SecBot SecBot

COAG

Hemab Therapeutics Holdings, Inc.
Nasdaq· CIK 0002114044 Biotech & Drug Discovery
$39.06 −1.80 (−4.41%)
Nov 16 4:00 PM ET · prev $40.86
Market cap
$1.8B
Small cap
Consensus
Buy
92% Buy or better · 12 analysts
Median target
$64.00
+64% · range $54.00–70.00
Since first trade
+14.9%
from $34.00 · May 1
30 days
+21.7%
from $32.09
Range since listing
$24.98–54.94
−29% from high · low Jun 12
Avg volume 20D
522.7K
shares / day
Short interest
3.31M
≈7.1% of shares · +4.6%
Days to cover
7.3
at average volume
Insider net
+$55.5M
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
15
analyzed by SecBot
SecBot read BULLISH 6 reports · 90 days
Balance 0 bearish · 1 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 5/6

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $55.5M. No open-market sales.

  • InstitutionsBULLISH

    Q3 2026: 14 added (0 new), 3 trimmed or exited.

  • AnalystsBULLISH

    11 of 12 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.510 → −$0.549 over 90 days. 0 up, 2 down in 30 days.

  • Short sellersSTEADY

    Short interest +4.6% to 3.31M shares. 7.3 days to cover, ≈7.1% of shares.

  • TrendUPTREND

    6% above its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED1,399,039$43.1M
STATE STREET CORPDOUBLED927,245$28.6M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED502,042$15.5M
VANGUARD PORTFOLIO MANAGEMENT LLCDOUBLED137,143$4.2M
UBS Group AGDOUBLED106,659$3.3M
MORGAN STANLEYDOUBLED30,137$929.4K
MANUFACTURERS LIFE INSURANCE COMPANY, THEADD24,428$753.4K
MARSHALL WACE, LLPNEAR_EXIT17,208$530.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 92% rate it Buy or better
Strong Buy4Buy7Hold1Sell0Strong Sell0
12-month targets · 7 analysts

Price is below the lowest target. Median implies +64%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 9, 2026LifeSci Capital
INITIATE
INITIATEOutperform
Oct 15, 2026JP Morgan
INITIATE
INITIATEOverweight
Oct 12, 2026Rodman & Renshaw
INITIATE
INITIATEBuy
Aug 12, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Aug 11, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jul 13, 2026Jefferies
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$55.5M
bought · 1 insider
$0
sold · 0 insiders
DateInsiderTypeValue
Sep 24, 2026
Walbert Keli
Director
Sep 24, 2026
AWARD36,000 sh
Jun 16, 2026
RA CAPITAL MANAGEMENT, L.P.
10%+ Owner
Jun 16, 2026
BUY$1.5M
Jun 15, 2026
RA CAPITAL MANAGEMENT, L.P.
10%+ Owner
Jun 15, 2026
BUY$153.0K
May 20, 2026
RA CAPITAL MANAGEMENT, L.P.
10%+ Owner
May 20, 2026
BUY$24.8K
May 19, 2026
RA CAPITAL MANAGEMENT, L.P.
10%+ Owner
May 19, 2026
BUY$94.9K
May 12, 2026
RA CAPITAL MANAGEMENT, L.P.
10%+ Owner
May 12, 2026
BUY$159.0K
May 11, 2026
RA CAPITAL MANAGEMENT, L.P.
10%+ Owner
May 11, 2026
BUY$643.0K
May 11, 2026
RA CAPITAL MANAGEMENT, L.P.
10%+ Owner
May 11, 2026
BUY$346.2K

Earnings setup

Estimates
−$0.55
EPS estimate, this quarter
−8%
estimate change, 90 days
0↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.55-$0.57–-$0.54-7.7%$0.00
Next Q-$0.61-$0.64–-$0.58-5.2%$0.00
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
3,305,474
shares short
+4.6%
vs prior settlement
7.3
days to cover
≈7.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

15 filings · 4 press releases · 1 bullish · 0 bearish · 1 mixed · 13 neutral
All COAG filing & press-release reports (19)